BIOHK2022: Hong Kong needs a more integrated and harmonised ecosystem to become a biotech fundraising hub, panellists say

December 15, 2022 Chin@Strategy

From left, Bin Li of Lake Bleu Capital, Vijay Karwal of AffaMed Therapeutics, Donald Lung, CFO of Antengene and Yinxiang Wang, chairman and CEO of Jacobio Pharma, take part in a panel discussion on ‘Capital Market for Healthcare Post Pandemic’ at BIOHK2022 on Thursday. Photo: Handout

South China Morning Post

Related posts

• 

  June 17, 2025 Media Library 0

  China pushes regional finance bank as Russia pivots to Asia: analysts

  As the United States scales back foreign aid and increases financial sanctions through long-arm jurisdiction, analysts...

• 

  June 17, 2025 Media Library 0

  DeepSeek rival MiniMax says its first AI reasoning model halves compute of R1

  Shanghai-based artificial intelligence (AI) start-up MiniMax has launched an open-source reasoning model that it said requires...

• 

  June 17, 2025 Media Library 0

  China’s C929 jet secures Western tech as manufacturer signs parts deals

  China’s chief civilian aircraft maker has secured deals to buy Western-made parts for its first widebody...